Compare Medpace Holdings Inc (MEDP) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs ProShares Ultra Semiconductors — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while ProShares Ultra Semiconductors trades at $95 (market cap $2.94B). The key difference: Medpace Holdings Inc is far larger — about 5.7× ProShares Ultra Semiconductors's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and ProShares Ultra Semiconductors for 29 Days on average.
| MEDP | USD | |
|---|---|---|
Market Cap | $16.82B | $2.94B |
Volume | 223,093 | 630,148 |
Sector | Health | Leveraged / Inverse |
52-Week High | $630.19 | $113.53 |
52-Week Low | $393.42 | $43.19 |
Typical Hold Time | 14 Days | 29 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
USD stock trades at $102.77, down 0.96% on the day, with a bullish technical signal driven by strong moving average alignment. The stock shows overbought conditions on shorter-term RSI readings while maintaining positive momentum indicators. Recent corporate actions include a scheduled dividend payment of $0.13 per share for September 2026. Price levels indicate support near $100-$102 and resistance at $103-$105.
The stock's technical strength contrasts with limited fundamental data availability. Investors face uncertainty regarding valuation metrics and profitability measures, requiring careful assessment of upcoming financial disclosures. Near-term price action will likely hinge on market sentiment and technical levels given the current information gap on core business fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
